BioSpace News Archive

CONMED Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on October 7, 2019 to all shareholders of record as of September 13, 2019.

Navitus Health Solutions announced today the retirement of its long-time President and CEO, Terry Seligman, R.Ph., effective this week. Initially he planned to retire at the end of the year; however health issues have accelerated his retirement plans

The global hairy cell leukemia therapeutics market is expected to post a CAGR of over 6% during the period 2019-2023, according to the latest market research report by Technavio.

AGS Health, a global leader in revenue cycle management services for US based healthcare providers, has been recognized by Aon as a Best Employer in India for the year 2019.

Today, the U.S. Food and Drug Administration granted approval to Turalio (pexidartinib) capsules for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not responsive to improvement with surgery.

Insmed Incorporated announced the granting of inducement awards to five new employees.

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted 14 newly-hired employees options to purchase an aggregate of 120,350 shares of Akebia’s common stock on July 31, 2019, as inducements material to each such employee’s entering into employment with Akebia.

Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that it will voluntarily replace certain NATESTO® lots released in the Canadian and South Korean markets, which is expected to cause temporary shortages in those markets.

Oncoceutics, Inc. announced that a series of presentations at the 2019 DIPG/DMG Symposium to be held August 2-3 in Sydney, Australia, will highlight ONC201 as a promising treatment for specific types of lethal brain cancer

BioCardia, Inc. (NasdaqCM: BCDA, BCDAW), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the pricing of its public offering of 1,666,667 units at a price to the public of $6.00 per unit.